Quarterly report pursuant to Section 13 or 15(d)

Revenues - Additional Information (Detail)

v3.7.0.1
Revenues - Additional Information (Detail)
 3 Months Ended
Feb. 27, 2017
USD ($)
Jan. 04, 2017
USD ($)
Jan. 04, 2017
EUR (€)
May 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2017
EUR (€)
Mar. 31, 2016
USD ($)
Dec. 31, 2016
USD ($)
Deferred Revenue Arrangement [Line Items]                
Revenues from product sales         $ 0      
Non-current deferred revenue         32,352,662     $ 1,409,483
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member]                
Deferred Revenue Arrangement [Line Items]                
Deferred revenue         3,100,000   $ 6,000,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Upfront Payment Arrangement [Member]                
Deferred Revenue Arrangement [Line Items]                
Collaboration agreement, license upfront payment         $ 6,500,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Research Services [Member]                
Deferred Revenue Arrangement [Line Items]                
Research collaboration agreement, estimated period         20 months 20 months    
Collaboration agreement, revenue recognized         $ 1,000,000   $ 1,200,000  
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Research Services [Member] | Extension Term [Member]                
Deferred Revenue Arrangement [Line Items]                
Research collaboration agreement, estimated period         5 years 5 years    
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments         $ 406,500,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Development Milestones [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments         282,700,000      
FHoffmann La Roche Ltd and Hoffmann La Roche Inc [Member] | Collaborative Arrangement [Member] | Maximum [Member] | Sales Milestone Payments [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments         119,900,000      
ASKA Pharmaceutical Co Ltd [Member]                
Deferred Revenue Arrangement [Line Items]                
Deferred revenue         2,750,000      
Total allocable arrangement consideration $ 2,750,000              
Evaluation Period 60 days              
ASKA Pharmaceutical Co Ltd [Member] | Upfront Payment Arrangement [Member]                
Deferred Revenue Arrangement [Line Items]                
Upfront option payment $ 2,750,000              
ASKA Pharmaceutical Co Ltd [Member] | Collaborative Arrangement [Member]                
Deferred Revenue Arrangement [Line Items]                
Collaboration agreement, milestone payments         0      
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Upfront Payment Arrangement [Member]                
Deferred Revenue Arrangement [Line Items]                
Total allocable arrangement consideration       $ 32,000,000   € 30,000,000    
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member]                
Deferred Revenue Arrangement [Line Items]                
Deferred revenue         2,900,000      
Non-current deferred revenue         28,900,000      
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Upfront Payment Arrangement [Member]                
Deferred Revenue Arrangement [Line Items]                
Collaboration agreement, license upfront payment   $ 32,000,000 € 30,000,000          
Collaboration agreement, revenue recognized         $ 500,000      
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Future Lead Product [Member] | Maximum [Member] | Development Milestones [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments | €     569,000,000          
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Future Lead Product [Member] | Maximum [Member] | Sales Milestone Payments [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments | €     515,000,000          
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Other Programs [Member] | Maximum [Member] | Development Milestones [Member] | Substantive [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments | €     163,000,000          
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Other Programs [Member] | Maximum [Member] | Development Milestones [Member] | Non Substantive [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments | €     406,000,000          
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Other Programs [Member] | Maximum [Member] | Sales Milestone Payments [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments | €     193,000,000          
Les Laboratoires Servier and Institut de Recherches Internationales Servier [Member] | Collaborative Arrangement [Member] | Other Programs [Member] | Maximum [Member] | Sales Milestone Payments [Member] | Non Substantive [Member]                
Deferred Revenue Arrangement [Line Items]                
Contractual agreement, potential payments | €     € 515,000,000